Precision Radiotherapy, SBRT, Shows Promise as 1st Treatment for Low- and Medium-Risk Prostate Cancers

Precision Radiotherapy, SBRT, Shows Promise as 1st Treatment for Low- and Medium-Risk Prostate Cancers
Men newly diagnosed with low- or intermediate-risk prostate cancer may benefit more by being treated with high-dose stereotactic body radiotherapy (SBRT) as a first therapy than with other available radiotherapies, according to the results of a large and multi-center clinical trial. The data, recently announced at the 58th Annual Meeting of the American Society for Radiation Oncology (ASTRO) in a presentation

Knowledge is power when living with prostate cancer.

Get access to the web’s leading Prostate Cancer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

One comment

Leave a Comment

Your email address will not be published. Required fields are marked *